Overview
IASLC presents a one-hour, live session focused on key highlights from the 2024 Hot Topic in Basic & Translational Science Conference. This webinar will serve as a platform to share cutting-edge research to advance the understanding and treatment of non-small cell lung cancer, followed by a moderated Q&A discussion. Drs. Christian Rolfo and Kenichi Suda will moderate the program and lead the discussion following the panel presentations by Drs. Pasi Jänne, Triparna Sen, and Lizza Hendricks. Highlights presented and discussed include Combination Strategies to Overcome TKI Resistance, Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation, and Antibody-Drug Conjugates as Potential Tools to Overcome TKI Resistance.
- To outline ongoing clinical trials on combination strategies to prevent or delay the emergence of acquired resistance
- To explain the underlying basic/translational mechanisms of TKI resistance
- To identify SCLC transformation as one of acquired resistances
- To explain some potential molecular mechanisms underlying SCLC transformation.
- To explain the basics of antibody-drug conjugates.
- To illustrate the mechanisms of ADC overcoming TKI resistance
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.
The International Association for the Study of Lung Cancer designates the live format for this educational activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
- To outline ongoing clinical trials on combination strategies to prevent or delay the emergence of acquired resistance
- To explain the underlying basic/translational mechanisms of TKI resistance
- To identify SCLC transformation as one of acquired resistances
- To explain some potential molecular mechanisms underlying SCLC transformation.
- To explain the basics of antibody-drug conjugates.
- To illustrate the mechanisms of ADC overcoming TKI resistance
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.
The International Association for the Study of Lung Cancer designates the live format for this educational activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Share
Participants
Christian Rolfo
MD, PhD, MBA, Dr.hc.
Director, Division of Medical Oncology and Associate Director for Early Phase Clinical Trials
Arthur G. James Cancer Hospital and Solove Research Institute
Ohio State University Comprehensive Cancer Center
Professor, Department of Medicine Ohio State University College of Medicine
Kenichi Suda
MD
Associate Professor in the Division of Thoracic Surgery
Kindai University School of Medicine
Pasi Janne
MD, PhD
Professor of Medicine
Dana Farber Cancer Institute, Harvard Medical School
Triparna Sen
PhD
Associate Professor, Co-Director, Lung Cancer PDX Program, Department of Oncological Sciences
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Lizza Hendriks
MD, PhD
Assistant Professor
Research Institute GROW, School for Oncology and Developmental Biology of Maastricht University